⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RNXT News
RenovoRx, Inc. Common Stock
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
globenewswire.com
RNXT
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
globenewswire.com
RNXT
Form 8-K
sec.gov
RNXT
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
globenewswire.com
RNXT
RenovoRx Announces $10 Million at Market Private Placement
globenewswire.com
RNXT
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
globenewswire.com
RNXT
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
globenewswire.com
RNXT
RenovoRx Establishes RenovoCath® Medical Advisory Board
globenewswire.com
RNXT
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
globenewswire.com
RNXT
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
globenewswire.com
RNXT